ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Comparison of the nephroprotective effect of [6]-gingerol and the [6]-gingerol-β-cyclodextrin complex against cisplatin-induced AKI.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cisplatin is an antineoplastic agent effective for the treatment of several cancers. However, due to its nephrotoxicity, its use is limited. Acute kidney injury (AKI) induced by cisplatin is caused by inflammation, apoptosis, and oxidative stress in renal tubular cells. Natural compounds derived from ginger (Zingiber officinale) such as [6]-gingerol, possess anti-inflammatory and antioxidant properties. This study explores the protective effects of [6]-gingerol and its β-cyclodextrin complex ([6]-gingerol-β-CD) on cisplatin-induced AKI in mice. We hypothesize that complexing [6]-gingerol with β-cyclodextrin would enhance its solubility and reduce its pungency, making it more suitable for clinical use. Additionally, we aim to determine whether β-cyclodextrin complexation can improve the oral bioavailability of [6]-gingerol without compromising its therapeutic efficacy. The minimum dose of cisplatin required to induce AKI was determined to be 15 mg/kg. Female Swiss mice (n = 6-8) were divided into four groups: control, cisplatin (15 mg/kg), [6]-gingerol (12.5 mg/kg), and [6]-gingerol-β-CD (12.5 mg/kg). The treatments were administered orally for 5 days. On the third day, cisplatin was administered intraperitoneally (i.p.), and the animals were euthanized after 5 days. All biochemical parameters investigated, such as plasma urea and creatinine, urinary gamma GT, urinary protein, MPO, and GSH were altered by cisplatin. The parameters evaluated in this study were categorized into renal function, inflammation, and oxidative stress. Both [6]-gingerol and complexed gingerol effectively restored most of the evaluated parameters to control levels. Following these analyses, we investigated the JAK/STAT pathway and observed that gingerol deactivates this pathway, thereby preventing cisplatin-induced nephrotoxicity. In conclusion, β-CD complexation did not interfere with [6]-gingerol therapeutic, emphasizing its indication for future clinical tests. Further analysis showed that [6]-gingerol prevented cisplatin nephrotoxicity by deactivating JAK/STAT signaling pathway.
Indexed as
Identifiers
40014121What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.